Products for Research Use Only
RegisterLogin

SKLB-163

CAT: 0804-HY-120429-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-120429-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
SKLB-163 is an orally active inhibitor for Rho GDP-dissociation (RhoGDI) . SKLB-163 inhibits highly expressed RhoGDI tumor cell proliferation and migration, and increases radiosensitivity of tumor cells. SKLB-163 induces cancer cell Apoptosis[1][2].
CAS Number
1255099-06-9
UNSPSC
12352005
Target
Apoptosis
Type
Reference compound
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/sklb-163.html
Solubility
10 mM in DMSO
Smiles
O=C(CSC1=NC2=CC=C(C=C2S1)NC(CCl)=O)NCC3=CC=CC=C3
Molecular Formula
C18H16ClN3O2S2
Molecular Weight
405.92
References & Citations
[1]He J, et al. Antitumor and radiosensitizing effects of SKLB-163, a novel benzothiazole-2-thiol derivative, on nasopharyngeal carcinoma by affecting the RhoGDI/JNK-1 signaling pathway. Radiother Oncol. 2018 Oct;129 (1) :30-37.|[2]Peng X, et al. SKLB-163, a new benzothiazole-2-thiol derivative, exhibits potent anticancer activity by affecting RhoGDI/JNK-1 signaling pathway. Cell Death Dis. 2014 Mar 27;5 (3) :e1143.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Related Products

CatalogName
HY-18947-01SKLB-23bb
HY-178114SKLB-0124
HY-177497SKLB-03220
HY-176848-01SKLB-Y13
HY-173572-01SKLB-11A
HY-173119-01SKLB-D18
HY-178102SKLB-0266
HY-144217-01SKLB-197
HY-122860SKLB-C05
HY-163035-01EM-163

Alternative Products

CatalogName
M27829-01SKLB-163
QXC58006-01SKLB-23bb
TRC-S555010-250MGSKLB-1028
T34656-01SKLB 1028
BUP10703-01SKLB 610
GTR19280539-01SKLB-0124
GTR19258231-01SKLB-D18
C03652-1gSKLB-11A
C01495-5mgSKLB-197
GTR19257669-01SKLB-03220

Popular Products